CX NEWS
Ulf Teichgräber discusses the EffPAC trial 12-month results which were presented for the first time at CX 2018
Ulf Teichgräber discusses the EffPAC trial 12-month results which were presented for the first time at CX 2018 Ulf Teichgräber, Jena, Germany
EVAS is associated with a reduction in all-cause mortality
EVAS is associated with a reduction in all-cause mortality Marc Schermerhorn, Boston, United States
Podium 1st: Lutonix AV IDE interim 24 month update
Podium 1st: Lutonix AV IDE interim 24 month update Kate Steiner, Stevenage, United Kingdom
“Promising” initial results for sirolimus-eluting bioresorbable scaffold in DESappear trial
Andrew Holden The sirolimus-eluting bioresorbable peripheral scaffold system (Prava; Elixir Medical) is designed to treat stenoses and occlusion in the superficial femoral artery. Prava was first implanted in October 2016 and will [...]
CX 2018: Landmark EVRA trial provides first Level 1 evidence for early endovenous ablation
The first full results of the Early Venous Reflux Ablation (EVRA) ulcer study were presented at the Charing Cross Symposium yesterday. The presentation was accompanied by simultaneous publication in the New England Journal of [...]
Majority of CX audience decides endovascular-first strategy for critical limb ischaemia is a concept without evidence
At the CX Great Debate held yesterday, vascular and endovascular surgery titans went head-to-head to debate the contentious topic “Endovascular-first strategy for critical limb ischaemia is a concept without evidence”. Arguing in favour of [...]
